Organon OGN Acquired in-process research and development and milestones
Acquired in-process research and development and milestones at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired.
The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Organon's acquired in-process research and development and milestones.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Organon's acquired in-process research and development and milestones?
- Organon (OGN) reported acquired in-process research and development and milestones of $0 in Q1 2026.
- How has Organon's acquired in-process research and development and milestones changed year-over-year?
- Organon's acquired in-process research and development and milestones decreased by 100.0% year-over-year, from $6M to $0.
- What is the long-term trend for Organon's acquired in-process research and development and milestones?
- Over 3 years (2021 to 2025), Organon's acquired in-process research and development and milestones has grown at a -61.4% compound annual growth rate (CAGR), from $104M to $6M.
- What does acquired in-process research and development and milestones mean?
- This metric represents the costs associated with acquiring in-process research and development projects or milestone payments made to third parties for pharmaceutical assets that have not yet reached commercial viability. It reflects the company's strategy of augmenting its internal pipeline through external innovation and strategic partnerships. Monitoring this figure helps investors assess the capital intensity of the company's external growth strategy and the potential future value of its R&D portfolio.